Skip to main content
. 2020 Jan 10;104(3):251–258. doi: 10.1111/ejh.13368

Figure 2.

Figure 2

Comparison of patients with classical Hodgkin lymphoma receiving bendamustine and brentuximab vedotin in different therapy lines. Progression‐free survival (PFS) of patients treated in earlier lines was significantly higher than of those treated later (first‐line median PFS not reached, 1‐y PFS 100%; second‐ and third‐line median PFS not reached, 1‐y PFS 87.1%; fourth‐ and fifth‐line median PFS 8.0 mo (95% CI: 3.2‐12.8 mo), 1‐y PFS 33.3%; overall P = .048)